Institute for Tuberculosis Research

College of Pharmacy
masthead

Faculty

Scott Franzblau Scott Franzblau, Ph.D., Director. Previously Chief of Pharmacology Research at the National Hansen's Disease Center. Over twenty years experience in evaluation of new drug candidates for leprosy and tuberculosis, including clinical trials in the former. At University of Illinois at Chicago since 2000. Oversees the screening and biological evaluation of compounds and extracts.
Sanghyun Cho Sanghyun Cho, Ph.D., Research Assistant Professor. Dr. Cho is a Molecular Biologist who was recruited from the Korean Institute for Tuberculosis. His work involves new assay development for high throughput screening and identification of the target of new anti-TB lead compounds.
Larry Klein Larry L. Klein, Ph.D. , Research Professor. After receiving his Chemistry Ph.D. at Michigan State University, Dr. Klein served as a Research Fellow at Harvard, on the Chemistry faculty at Texas A&M University, and worked 22 years as a Medicinal Chemist in Infectious Disease Research Division at Abbott. He leads a group of chemists in the synthesis of new anti-TB compounds.
Olga Krasnykh Olga Krasnykh, Ph.D. , Research Assistant Professor at ITR and Head of Laboratory of Medicinal Chemistry at Perm Pharmaceutical Academy in Russia. Dr. Krasnykh is working on the synthesis of anti-TB heterocyclic compounds.
Birgit Jaki Birgit Jaki, Ph.D. Pharm.D. , Research Assistant Professor. Dr. Jaki is a licensed pharmacist whose doctoral research in the lab of Dr. Otto Sticher at the Swiss Federal Institute of Technology (ETH, Zurich), focused on natural products of cyanobacteria. She investigates the potential of natural products as candidate anti-TB agents.
Maria Beconi Maria Beconi, Ph.D., Visiting Senior Research Scientist. Dr. Beconi is the former Director of Drug Metabolism at Abbott Labs with 15 years of industrial experience in drug metabolism/pharmacokinetics including positions at Merck, GlaxoSmithKline and Upjohn. She oversees drug metabolism/pharmacokinetics studies in the ITR.
Farah Farah Movahedzadeh, M.D. Ph.D., Research Assistant Professor. Dr. Movahedzadeh is a Molecular Biologist/Microbiologist who received a medical degree in Clinical Laboratory Sciences and also a Ph.D. in Molecular Biology from the National Institute for Medical Research in Britain. She has worked 14 years on the molecular genetics of M. tuberculosis. Her main interests include essential genes, virulence, gene regulation and expression, cell wall biosynthesis, and identification of novel drug targets.
Guido F Pauli Guido F. Pauli, Ph.D. Pharm.D., Assistant Professor in the Dept. of Medicinal Chemistry and Pharmacognosy. Dr. Pauli is trained as both a Pharmacist and a Natural Products Chemist with broad expertise in natural products isolation, identification, quantification and purity determination, including qNMR. He leads the effort to study the metabolome of Mycobacteria and to discover novel anti-TB agents from natural products.
Pavel Petukhov Pavel Petukhov, Ph.D., Associate Professor in the Dept. of Medicinal Chemistry and Pharmacognosy. Dr. Petukhov is an expert in enzymology and protein crystallography and is involved with TB target-based drug discovery.
Andrew Mesecar Andrew Mesecar, Ph.D., Associate Professor in the Dept. of Medicinal Chemistry and Pharmacognosy. Dr. Mesecar is an expert in enzymology and protein crystallography and is involved with TB target-based drug discovery.
Brent Friesen Brent Friesen, Ph.D., Assistant Professor of Chemistry at Dominican University in River Forest (IL). Dr. Friesen received his graduate training in phytochemistry and biosynthesis at the University of Minnesota, Minneapolis (MN). He collaborates in the natural products division of ITR, and contributes as an expert in countercurrent separation technology.